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Review
Bleeding with direct oral anticoagulants vs warfarin:
clinical experience☆,☆☆,★
John Eikelboom, MD a,∗, Geno Merli, MD b
a Department of Medicine, Division of Hematology and Thromboembolism, McMaster University, Hamilton, Ont, Canada
b Departments of Surgery and Medicine, Jefferson Vascular Center, Thomas Jefferson University Hospitals, Philadelphia, PA
a b s t r a c ta r t i c l e i n f o
The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated following the introduc-
tion of a new generation of direct oral anticoagulants (DOACs). Interruption of DOAC therapy and supportive care
may be sufﬁcient for themanagement of patients who presentwithmild ormoderate bleeding, but in thosewith
life-threatening bleeding, a speciﬁc reversal agent is desirable. We review the phase 3 clinical studies of
dabigatran, rivaroxaban, apixaban, and edoxaban in patients with nonvalvular atrial ﬁbrillation, in the context
of bleeding risk and management.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
The vitamin K antagonists (VKAs), such as warfarin, have been the
standard and indeed, only, option for oral anticoagulant therapy for de-
cades. However, their use requires routine coagulation monitoring be-
cause genetic variation and interactions between warfarin and diet,
other drugs, and comorbidities produce variable and unpredictable an-
ticoagulant effects [1-3]. The time in therapeutic range is a determinant
of the efﬁcacy and safety of warfarin [4]. In 1 representative study, 62%
of warfarin-treated patients with nonvalvular atrial ﬁbrillation (NVAF)
who were admitted to the emergency department for ischemic strokes
had international normalized ratios (INRs) that were outside of the de-
sired therapeutic range [5].
The new generation of direct oral anticoagulants (DOACs) offers im-
portant advantages over warfarin, but the risk of bleeding with these
drugs—as with all anticoagulants—remains an ongoing safety concern.
The DOACs currently approved by the U.S. Food and Drug Administra-
tion (FDA) include the direct thrombin inhibitor dabigatran, which
was approved in 2010, and the more recently introduced direct factor
Xa (FXa) inhibitors rivaroxaban, apixaban, and edoxaban. In contrast
to warfarin, DOACs have a more rapid onset, predictable anticoagulant
effect, shorter half-life, [6-9] and few drug–drug and dietary interac-
tions [10-13]. Hence, they can be given in ﬁxed doses without routine
coagulation monitoring.
The severity of bleeding events with anticoagulant use ranges from
minor bleeding to life-threatening intracranial hemorrhages (ICHs) or
exsanguinating hemorrhages. Supportive measures for bleeding man-
agement in anticoagulated patients vary depending on the setting and
speciﬁc on-board therapy. Identifying the optimal management strate-
gy is a critical component of bleeding management. The landscape has
recently changed with the introduction of a speciﬁc rapidly acting re-
versal agent for dabigatran in the United States [14]. In this article we
brieﬂy review the phase 3 clinical studies of dabigatran, rivaroxaban,
apixaban, and edoxaban as compared with warfarin in the context of
bleeding risk and management. This article focuses on studies per-
formed in patients with NVAF. Postmarketing and “real-world” data
are presented by Villines et al [15] in this special issue. We will also
brieﬂy discuss the current strategies for assessing coagulation and gen-
eral measures for managing DOAC bleeding. Discussions of speciﬁc
DOAC reversal agents are presented by Pollack [16] and Milling et al
[17], elsewhere in this special issue.
Bleeding Risks in Phase 3 NVAF Trials of DOACS vs Warfarin
In phase 3 clinical trials, dabigatran, rivaroxaban, apixaban, and
edoxabanwere comparedwith VKAs for the prevention of stroke or sys-
temic embolism in NVAF. The incidence of major bleeding or a compos-
ite of major and nonmajor clinically relevant bleedingwere the primary
safety end points in these trials.
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Dabigatran
In the Randomized Evaluation of Long-term anticoagulation thera-
pY (RE-LY) study, 18,113 patients who had NVAF and risk of stroke
were randomized to dabigatran 110 mg twice daily or 150 mg twice
daily, or warfarin (adjusted doses with a target INR of 2-3), and were
followed for a median of 2.0 years [18]. In the primary publication of
the RE-LY study, rates of major bleeding were 3.11% per year in the
dabigatran 150-mg-twice-daily group (relative risk 0.93; 95% conﬁ-
dence interval [CI], 0.81-1.07; P = .31) and 2.71% per year in the
dabigatran 110-mg-twice-daily group (relative risk 0.80; 95% CI, 0.69-
0.93; P= .003) vs 3.36% per year in thewarfarin group [18]. Dabigatran
150 mg twice daily and 110 mg twice daily reduced the relative risk of
intracranial bleeding (both doses P b.001), and only dabigatran 150mg
twice daily increased the relative risk of major gastrointestinal (GI)
bleeding (P b.001) vs warfarin (Table 1) [18-22]. After completion of
the study, additional primary efﬁcacy and safety outcome events were
identiﬁed, and the rates of major bleeding were revised to 3.32% in
the dabigatran 150 mg twice-daily group (relative risk 0.93; 95% CI,
0.81-1.07; P = .32) and 2.87% in the dabigatran 110-mg-twice-daily
group (relative risk 0.80; 95% CI, 0.70-0.93; P = .003) vs 3.57% in the
warfarin group [23]. Inclusion of the newly identiﬁed events did not
change the study conclusions [23]. Overall, these results contributed
to the FDA approval of dabigatran etexilate for prevention of stroke
and systemic embolism in patients with NVAF [10]. As dabigatran
etexilate is predominantly eliminated in the urine (80% renal excre-
tion), [10] renal impairment can increase the exposure to dabigatran,
and thus, dose adjustment may be considered in this patient popula-
tion. For patients with a creatinine clearance (CrCl) of 15-30 mL/min,
the recommended dosage of dabigatran etexilate in the United States
is 75 mg twice daily. Patients with a CrCl of ≤30mL/min were excluded
from theRE-LY trial [24] and dosing recommendations for patientswith
a CrCl of b15mL/min or on dialysis are not provided [10] (Table 2). Out-
side of the United States, dabigatran 110mg twice daily is recommend-
ed for patients deemed to be at risk of stroke, including: elderly patients
(age ≥80 years), concomitant use of interacting drugs (eg, verapamil),
high bleeding risk (HAS-BLED score ≥3), or moderate renal impairment
(30-50 mL/min) [25-27].
In a subgroup analysis of the RE-LY study, the risk of major bleeding
was assessed according to age [28]. Dabigatran 110mg twice daily com-
pared with warfarin was associated with a lower risk of major bleeding
in younger patients (aged b75 years; 1.89% vs 3.04%; P b.001) and a
similar risk in older patients (aged ≥75 years; 4.43% vs 4.37%; P= .89).
Dabigatran 150 mg twice daily compared with warfarin was associated
with a lower risk of major bleeding in younger patients (2.12% vs 3.04%;
P b.001) and a trend toward a higher risk of major bleeding in older pa-
tients (5.10% vs 4.37%; P = .07). The similar or higher risk of major
bleeding was driven by rates of extracranial bleeding, primarily GI
bleeding; the risk of ICH was lower with both doses of dabigatran com-
pared with warfarin, irrespective of age. In a separate subgroup analysis
of the RE-LY cohort, the incidence of ICH during anticoagulation therapy
was evaluated by site (intracerebral, subdural, or subarachnoid), risk
factors, and outcomes [29]. The relative risk of intracerebral hemorrhage
was reducedwith dabigatran 150mg twice daily (relative risk 0.23; 95%
CI, 0.12-0.45; P b.001) and dabigatran 110 mg twice daily (relative risk
0.30; 95% CI, 0.16-0.54; P b.001) compared with warfarin. The relative
risk of subdural hemorrhages was only reduced with dabigatran
110 mg twice daily compared with warfarin (relative risk 0.27; 95% CI,
0.12-0.55; P b.001). Dabigatran 150 mg twice daily and 110 mg twice
daily did not signiﬁcantly reduce the risk of subarachnoid hemorrhages
compared with warfarin. Mortality following ICH was similar in patients
treated with dabigatran 150 mg twice daily (35%), dabigatran 110 mg
twice daily (41%), or warfarin (36%).
Bleeding management and outcomes were evaluated in a separate
analysis of the RE-LY cohort [30]. More patients in the dabigatran
150-mg-twice-daily (61.4%) vs warfarin group (49.9%) were treated Ta
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with blood transfusions (P b.001), and fewer patients in both dabigatran
groups were administered fresh frozen plasma (FFP) (dabigatran
150 mg twice daily, 21.6% and dabigatran 110 mg twice daily, 17.8%)
vs warfarin (30.2%; P b .005 and P b .001, respectively). The proportion
of major bleeding events requiring hospitalizationwas similar between
dabigatran 110 mg twice daily and 150 mg twice daily compared with
warfarin (51.2%, 61.8%, and 56.5%, respectively).
Rivaroxaban
In the Rivaroxaban Once daily oral direct factor Xa inhibition com-
pared with vitamin K antagonism for prevention of stroke and Embo-
lism Trial in Atrial Fibrillation (ROCKET AF), 14,264 patients with
NVAF who were at moderate-to-high risk for stroke were randomized
to rivaroxaban or warfarin and followed for a median of 1.94 years
[19]. Patients received ﬁxed-dose rivaroxaban (20 mg once daily or
15 mg once daily in patients with a CrCl of 30-49 mL/min) or adjusted
doses of warfarin (target INR of 2-3). The rates of any major bleeding
event (number per 100 patient-years) were similar between the
rivaroxaban group (3.6) and the warfarin group (3.4) (hazard ratio
[HR] 1.04; 95% CI, 0.90-1.20; P= .58) [19]. Rivaroxaban compared with
warfarin reduced the rate of ICH (HR 0.67; 95% CI, 0.47-0.93; P = .02)
[19,20] and increased the rate of major GI bleeding (HR 1.61; 95% CI,
1.30-1.99, P b.001) [20] (Table 1). Based on these safety and efﬁcacy
data, the FDA approved rivaroxaban 20 mg once daily for NVAF patients
with a CrCl of N50 mL/min and 15 mg once daily for those with a CrCl of
15-50 mL/min [13] (Table 2).
In a separate analysis of the ROCKET AF cohort, baseline factors that
were independently associated with major bleeding were: age, sex, di-
astolic blood pressure, history of chronic obstructive pulmonary disease,
prior GI bleeding, prior aspirin use, and anemia [31]. The relative risk of
major bleeding with rivaroxaban vs warfarin treatment was similar re-
gardless of age, whereas the risk of ICHwas reduced irrespective of age.
Rivaroxabanwas associated with reductions in various subtypes of ICH,
including intraparenchymal, intraventricular, and subdural compared
with warfarin (all P b.05; no HRs provided). Patients with a history of
GI bleeding who were treated with rivaroxaban were at higher risk of
major bleeding than those treated with warfarin (HR 2.33; 95% CI,
1.39-3.88; interaction P = .002), whereas the risk of GI bleeding was
similar between rivaroxaban and warfarin if there was no history of GI
bleeding (HR 1.00; 95% CI, 0.86-1.16).
Bleeding management and outcomes were evaluated in a separate
analysis of the ROCKET AF cohort [32]. Among patients who experi-
encedmajor bleeding, rivaroxaban compared with warfarin was associ-
ated with less frequent use of FFP (45 vs 81 units; odds ratio 0.43; 95%
CI, 0.29-0.66; P b.0001) and prothrombin complex concentrate (PCC)
(4 [0.9%] vs 9 [2.2%] patients). Outcomes after major bleeding, including
duration of hospitalization (5 days vs 6 days) and all-cause death (20.4%
vs 26.1%; HR 0.688; 95% CI, 0.455-1.042) were similar among patients
treated with rivaroxaban or warfarin.
Apixaban
In the Apixaban for Reduction In STroke andOther ThromboemboLic
Events in Atrial Fibrillation (ARISTOTLE) study, 18,201 patients with AF
and at least one additional risk factor for stroke were randomized to
apixaban or dose-adjusted warfarin (target INR 2-3) and followed for
a median of 1.8 years [21]. Apixaban was administered twice daily as
ﬁxed doses of either 5 mg or 2.5 mg according to age, body weight,
and serum creatinine level. The rates of major bleeding were 2.13%
per year in the apixaban group vs 3.09% per year in the warfarin group
(HR 0.69; 95% CI, 0.60-0.80; P b.001). The rate of intracranial bleeding
was reduced with apixaban compared with warfarin (0.33% vs 0.80%
per year; HR 0.42; 95% CI, 0.30-0.58; P b.001). In contrast, the rate of
GI bleeding did not differ between apixaban and warfarin (0.76 vs
0.86% per year; HR 0.89; 95% CI, 0.70-1.15; P = .37) (Table 1) [21].
These safety data contributed to the FDA approval of apixaban 5 mg
twice daily for patients with NVAF [11]. Apixaban 2.5 mg twice daily is
recommended for patients with at least 2 of the following characteristics:
≥80 years of age, weight ≤60 kg, or serum creatinine ≤1.5mg/dL (Table 2).
In a separate analysis, Hylek et al [33] evaluated clinical outcomes
associatedwithmajor bleeding in patients enrolled in ARISTOTLE. Base-
line factors that were independently associatedwithmajor hemorrhage
were: older age, prior hemorrhage, prior stroke or transient ischemic at-
tack, diabetes, a lower CrCl (b85 mL/min/1.73 m[2]), decreased hemat-
ocrit level (b45%), use of aspirin therapy, and use of nonsteroidal anti-
inﬂammatory drugs [33]. Adverse events following major extracranial
hemorrhage occurred less frequently in the apixaban than in thewarfa-
rin group, including fewer hospitalizations (1.05% vs 1.41% per 100
patient-years; HR 0.75; 95% CI, 0.61-0.92; P= .0052) and fewer transfu-
sions (0.89% vs 1.25% per 100 patient-years; HR 0.71; 95% CI, 0.57-0.89;
P = .0025) [33]. In addition, death within 30 days following major
Table 2
Dosage and Administration of DOACs for Patients with NVAF According to Renal Function∗
Drug Renal Function (CrCl) Dosage and Administration
Dabigatran etexilate [10] N30 mL/min 150 mg BID
15-30 mL/min 75 mg BID
b15 mL/min or on dialysis Not provided†
Rivaroxaban [13] N50 mL/min 20 mg QD with evening meal
15-50 mL/min 15 mg QD with evening meal
b15 mL/min Not provided‡
Apixaban [11] No dose adjustment is recommended for patients with RI alone (including patients with ESRD
[b15 mL/min] and maintained on hemodialysis)
5 mg BID
For patients with at least 2 of the following characteristics: ≥80 y of age, weight ≤60 kg,
or serum creatinine ≤1.5 mg/dL
2.5 mg BID
Edoxaban [12] N95 mg/dL Avoid use
N50 to ≤95 mL/min 60 mg QD
15-50 mL/min 30 mg QD
b15 mL/min Not recommended
BID = twice daily; CrCl = creatinine clearance; DOAC= direct oral anticoagulant; NVAF = nonvalvular atrial ﬁbrillation; QD= once daily; RI = renal impairment.
∗ Information in this table is based on the U.S. prescribing information for the available agents. Please see individual prescribing information for warnings and precautions.
† Dosing recommendations cannot be provided for patients with CrCl b15 mL/min or on dialysis [10].
‡ Clinical efﬁcacy and safety studies with Xarelto did not enroll patients with end-stage renal disease on dialysis [13].
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hemorrhage occurred half as often with apixaban vs warfarin (36 vs 71
events; HR 0.50; 95% CI, 0.33-0.74; P b.001).
Edoxaban
In the Effective aNticoaGulation with factor xA next GEneration in
Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (EN-
GAGE-AF TIMI 48), 21,105 patients with moderate-to-high-risk AF
were randomized to warfarin, high-dose (HD) edoxaban (60 mg) once
daily or low-dose (LD) edoxaban (30 mg) once daily, and followed for
a median of 2.8 years [22]. The dose of edoxaban was reduced by 50%
in patients with an estimated CrCl of 30-50 mL/min, body weight of
≤60 kg, or the concomitant use of potent P-glycoprotein inhibitors at
baseline or during the course of the study. The annualized rate of
major bleeding in patients receiving HD edoxaban was 2.75% (HR
0.80; 95% CI, 0.71-0.91; P b.001) and 1.61% in patients receiving LD
edoxaban (HR 0.47; 95% CI, 0.41-0.55; P b.001), compared with 3.43%
in the warfarin group. Rates of ICH were reduced with HD edoxaban
(0.39%; HR 0.47; 95% CI, 0.34-0.63) and LD edoxaban (0.26%; HR 0.30;
95% CI, 0.21-0.43) relative to warfarin (0.85%; both doses P b.001). Gas-
trointestinal bleeding occurred more frequently with HD edoxaban
(1.51%; HR 1.23; 95% CI, 1.02-1.50; P = .03) and less frequently with
LD edoxaban than warfarin (0.82% vs 1.23%; HR 0.67; 95% CI, 0.53-
0.83; P b.001) (Table 1). Based on these data, edoxaban 60 mg once
daily was approved by the FDA for patients with NVAF and a CrCl of
N50 to ≤95 mL/min [12]. A dose adjustment to edoxaban 30 mg once
daily is recommended in patients with a CrCl of 15-50mL/min (Table 2).
In a subgroup analysis, both doses of edoxabanwere associatedwith
reductions in various subtypes of ICH, including parenchymal, sub-
arachnoid, and subdural or epidural bleeds [34]. Both edoxaban doses
also reduced the composite outcome of death, nonfatal stroke, or
ICH (HR 0.88; P = .003 for HD edoxaban, and HR, 0.90; P = .021 for
LD edoxaban) comparedwith warfarin. In a separate subgroup analysis,
Ruff et al [35] reported that reducing edoxaban dose based on
prespeciﬁed clinical factors (deﬁned above) maintained the anticoagu-
lant efﬁcacy of edoxaban and was associated with a reduced risk of
major bleeding compared with warfarin.
In summarizing all the above studies, major bleeding risk was re-
duced with apixaban (5 or 2.5 mg) twice daily, edoxaban (60 mg and
30 mg) once daily, and dabigatran 110 mg twice daily vs warfarin,
and rivaroxaban (20 or 15 mg) once daily and dabigatran 150 mg
twice daily had a similar bleeding risk vs warfarin. The risk of major
GI bleeding was similar with apixaban (5 or 2.5 mg) twice daily and
dabigatran 110 mg twice daily vs warfarin, and increased with
rivaroxaban (20 or 15 mg) once daily and dabigatran 150 mg twice
daily vs warfarin. The risk of GI bleeding with edoxaban was greater
with edoxaban 60 mg once daily and lower with edoxaban 30 mg
once daily. Intracranial bleeding risk was reduced with all DOACs that
were compared with warfarin.
Current Strategies for the Assessment and Management of DOAC
Bleeding
DOACs do not require routine monitoring [18-22] as is necessary
with warfarin, but laboratory measurement of blood levels or anticoag-
ulant activity may be helpful during an emergent bleeding situation or
in a number of other settings. Liquid chromatography tandem mass
spectrometry is a quantitative method of measuring DOAC concentra-
tion but is not a practical option for routine clinical use. In some circum-
stances, commonly available coagulation tests such as the activated
partial thromboplastin time (aPTT), prothrombin time, and thrombin
time (TT) can provide qualitative assessments of the presence or ab-
sence of an anticoagulant effect, but their sensitivity differs depending
on the agent. Speciﬁc assays, including dilute thrombin time, ecarin
clotting time (ECT), ecarin chromogenic assays, and chromogenic anti-
FXa assays can be used to quantify drug levels accurately but are not
yet widely available in the United States [36-39]. Applications of these
assays to speciﬁc DOACs are summarized in Table 3 and will be
discussed in further detail by Levy et al [40] in this special issue.
Rescue Therapies for Life-Threatening Bleeding Events in
DOAC-Anticoagulated Patients
Until recently there was no DOAC-speciﬁc reversal agent available,
andnonspeciﬁc hemostatic products havebeenused in bleedingmanage-
ment of DOAC-anticoagulated patients. Strategies for managing bleeding
complicationswith nonspeciﬁc hemostatic agents are different in patients
anticoagulated with DOACs compared with warfarin. In the presence of
warfarin, which has a long half-life, nonspeciﬁc hemostatic products in-
cluding FFP and PCCs replenish clotting factors and their effects can be
sustained with the addition of vitamin K [41]. In contrast, circulating
DOACswill also inhibit the exogenous clotting factors, and FFPmaynot ef-
fectively counteract DOAC-mediated anticoagulation.[27,42] The PCCs
contain high concentrations of vitamin K-dependent coagulation factors
(Table 4), [27, 43-47] whereas recombinant FVIIa (rFVIIa) contains high
concentrations of coagulation FVIIa. Vitamin K does not reverse the anti-
coagulant effect of DOACs [10-13]. Antiﬁbrinolytic agents can be used in
patients with bleeding, [48] but their efﬁcacy is unproven [43].
The nonactivated PCCs, including 4-Factor PCC and 3-Factor PCC
may be effective formanagement of bleeding in patients anticoagulated
with apixaban, [11] dabigatran, [10] rivaroxaban, [13] or edoxaban
[49,50]. The PCCs raise the levels of coagulation factors that have been
inhibited by DOACs. Their use in patients treated with DOACs is primar-
ily based on studies of 4-Factor PCC in animal models of bleeding [51-
53] and healthy subjects [44,45,50,54]. A retrospective study of 18 pa-
tients treatedwith rivaroxaban or apixaban and experiencing traumatic
ICH suggested that 4-Factor PCC reduces hemorrhagic complications
and hematoma expansion [55]. In a bleeding model of pigs
anticoagulated with dabigatran, 4-Factor PCC reduced blood loss and
Table 3
Available Assays for Measurement of DOAC Activity
Useful
Laboratory Test
Dabigatran Rivaroxaban Apixaban Edoxaban
Strong ECT Chromogenic
anti-FXa
Chromogenic
anti-FXa
Chromogenic
anti-FXa
TT/dTT PT∗ PT
aPTT
Weak PT/INR
aPTT = activated partial thromboplastin time; DOAC = direct oral anticoagulant; dTT =
dilute thrombin time; ECT = ecarin clotting time; FXa = factor Xa; INR = international
normalized ratio; PT = prothrombin time; TT = thrombin time.
∗ PT reagent neoplastin has the most linear correlation.
Table 4
Currently Available Blood Products for Rescue Management in DOAC Bleeding
(Rivaroxaban and Apixaban)
Product Factors Dosage and Administration∗
3-Factor PCC II, IX, X 50 U/kg, IV
May repeat Q 12 h
4-Factor PCC II, VII, IX, X, Proteins C and S 50 U/kg, IV;
One time dose
DOAC = direct oral anticoagulant; IV = intravenous; PCC = prothrombin complex con-
centrate; Q 12 h = every 12 hours.
∗ Dosage and administration recommendations are based on clinical information [25,
43-45] and expert opinion, as the use of PCCs to reverse the anticoagulant effects of DOACs
is not an approved indication in the United States [46,47].
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the risk of mortality; high-dose 4-Factor PCC resulted in overcorrection
of thrombin generation, but no thromboembolic complications were
observed [53]. Four-Factor PCC had no impact on laboratory tests of
the anticoagulant action of dabigatran in a study of nonbleeding healthy
subjects (PCC did not restore aPTT, ECT, or TT) despite evidence that it
improves hemostasis. In the same study, 4-Factor PCC immediately
and completely normalized the prothrombin time [45]. In phase 1 stud-
ies of healthy volunteers treated with edoxaban that underwent punch
biopsy, 4-Factor PCC completely reversed bleeding, restored endoge-
nous thrombin potential, and partially reversed thrombin time [50].
Transient and dose-dependent increases in prothrombin fragment 1
and 2 (F1+2) with 3-Factor PCC may reﬂect possible procoagulant
risk [49].
Administration of the procoagulant rFVIIa is suggested for
anticoagulated bleeding patients in the U.S. prescribing information
for dabigatran etexilate [10] and apixaban [11]. In an ex vivo study of
healthy volunteers, rFVIIa normalized levels of coagulation markers,
however, it failed to restore ﬁbrin generation [56]. The impact of this
ﬁnding on restoration of hemostasis is unclear.
Speciﬁc reversal agents are being developed with the goal of im-
proving the management and outcomes of bleeding in DOAC-treated
patients. In addition to idarucizumab, a speciﬁc reversal agent for
dabigatran, [57] andexanet alfa is under evaluation for reversal of indi-
rect or direct FXa inhibitors, [58,59] while ciraparantag [60] is in clinical
trials for reversal of DOACs as well as other anticoagulants. These rever-
sal agents will be discussed in the papers by Pollack [16] and Milling
et al [17] in this special issue.
Conclusion
DOACs offer important safety advantages over VKAs because they
are at least as effective for the prevention of thromboembolism, are as-
sociated with lower rates of life-threatening and intracranial bleeding,
and aremore convenient because they can be given in ﬁxed doses with-
out routine coagulation monitoring. Commonly available general coag-
ulation tests have limitations for measurement of the anticoagulant
effects of DOACs. Speciﬁc assays are commercially available [61] but
have not been widely implemented. Speciﬁc reversal agents are being
introduced into clinical practice andwill help to streamline themanage-
ment of patients with bleeding and those who require urgent surgery.
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